• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Hub Group, Inc. - Class A Common Stock
Idemitsu Kosan Co. Ltd
Sage Therapeutics, Inc. - Common Stock
Salazar Resources Ltd Ord
Snipp Interactive Inc
Solar Energy Initiatives Inc
Strikeforce Technologies Inc
West Mining Corp
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

62.23 -0.60 (-0.95%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,637,766
Open 62.98
Bid (Size) 61.04 (100)
Ask (Size) 63.81 (100)
Prev. Close 62.83
Today's Range 61.74 - 63.39
52wk Range 33.76 - 63.39
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
October 15, 2026
From Exelixis, Inc.
Via Business Wire
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital ↗
October 12, 2026
Via Chartmill

Performance

52-Week Range 1.8% below 52-week high
62.23
33.7652W Low 63.3952W High
1 Week 1.8% below 1-week high
58.591W Low 63.391W High

Exelixis, Inc. - Common Stock (EXEL) traded between $33.76 and $63.39 over the past 52 weeks and last traded at $62.23, 1.8% below its 52-week high. Over the past week it ranged between $58.59 and $63.39.

Past 12 Months
+4.0%
+6.4%
+12.1%
+42.7%
+42.8%
+58.5%
1W +$2.41
1M +$3.74
3M +$6.70
6M +$18.62
YTD +$18.65
1Y +$22.98

EXEL was +58.5% over the past year, +42.7% over six months, +42.8% year to date, +4.0% in the last week.

12 Months vs Market
EXEL
+58.5%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months EXEL returned +58.5% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 1.11× 3-mo avg
Today 2,637,766 3-mo avg 2.4M
1W
2.8M
1M
2.4M
3M
2.4M
6M
2.5M
YTD
2.6M
1Y
2.7M

EXEL most recently traded 2,637,766 shares against a 3-month average daily volume of 2.4M.

More News

Read More
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup ↗
October 05, 2026
Via Chartmill
News headline image
Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B ↗
September 17, 2026
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle ↗
September 15, 2026
Via MarketBeat
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals ↗
August 22, 2026
Via Chartmill
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating ↗
August 06, 2026
Via Chartmill
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered ↗
August 05, 2026
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗
July 01, 2026
Via Chartmill
News headline image
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises ↗
September 14, 2026
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
September 01, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
August 31, 2026
From Exelixis, Inc.
Via Business Wire
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
June 09, 2026
Via Chartmill
News headline image
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
August 16, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Exelixis (EXEL) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
August 12, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Exelixis Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings
News headline image
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
August 05, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
July 24, 2026
Via The Motley Fool
Topics Economy
News headline image
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
July 10, 2026
Via The Motley Fool
News headline image
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
June 22, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
May 30, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
May 30, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
May 27, 2026
From Exelixis, Inc.
Via Business Wire

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 62.23
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 19.61B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 20B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap